For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Revenue | 0 | 0* | 0 | |
| Research and development | 31,454,000 | 39,811,000* | 34,068,000 | |
| General and administrative | 17,057,000 | 31,448,000* | 18,351,000 | |
| Restructuring | - | 3,747,000* | -172,000 | |
| Total operating expenses | 48,511,000 | 75,006,000* | 52,247,000 | |
| Loss from operations | -48,511,000 | -75,006,000* | -52,247,000 | |
| Interest expense | 473,000 | 472,000* | 473,000 | |
| Interest and other income, net | 161,000 | 1,091,000* | 709,000 | |
| Accretion of discount on investments, net | 1,229,000 | 2,260,000* | 1,679,000 | |
| Net loss | -47,594,000 | -72,127,000 | -50,332,000 | |
| Basic EPS | -0.42 | -0.652 | -0.45 | |
| Diluted EPS | -0.42 | -0.652 | -0.45 | |
| Basic Average Shares | 112,134,059 | 110,676,404 | 111,571,136 | |
| Diluted Average Shares | 112,134,059 | 110,676,404 | 111,571,136 | |
ROCKET PHARMACEUTICALS, INC. (RCKTW)
ROCKET PHARMACEUTICALS, INC. (RCKTW)